Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin vs Rivaroxaban for VTE Prophylaxis in Multiple Myeloma
NCT06580223Phase 3Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rivaroxaban in venous thromboembolism (VTE). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06580223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06580223.